 FRANCE 24 | Biogen Idec to Acquire Full Rights and Control of TYSABRI from Elan for ... Businessweek ... including uncertainty inherent in regulatory review of the transaction, our dependence on our three principal products, AVONEX™ (interferon beta-1a), TYSABRI and RITUXAN™ (rituximab), the importance of TYSABRI's sales growth, uncertainty of ... Biogen Idec to Acquire Full Rights and Control of TYSABRI(R) from Elan for ... |
